Local delivery of temozolomide via a biologically inert carrier (Temodex)

2025-02-05T22:54:38+01:00

Glioma is the most common brain malignancy. Standard first-line therapy for glioma includes surgery, radiotherapy and systemic administration of temozolomide. However, temozolomide does not reach the brain in sufficient doses when administered orally and has poor efficiency in more than half of the patients. Strategies to improve the treatment of glial malignancies are [...]

Local delivery of temozolomide via a biologically inert carrier (Temodex)2025-02-05T22:54:38+01:00

Double Bond aims at adaptive design for SI-053 Phase I

2018-11-20T23:39:15+01:00

Double Bond aims at adaptive design for SI-053 Phase I FRI, MAY 04, 2018 10:19 CET Double Bond Pharmaceutical (DBP) has signed a service contract with Cytel Inc, a leading provider of clinical research services and software, to develop an adaptive model-based study design for [...]

Double Bond aims at adaptive design for SI-053 Phase I2018-11-20T23:39:15+01:00
Go to Top